Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

  title={Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector},
  author={H Bobby Gaspar and Kathryn L. Parsley and Steven J Howe and Douglas King and Kimberly C. Gilmour and Jo Sinclair and Gaby S. Brouns and Manfred Schmidt and Christof von Kalle and Torben Barington and Marianne A Jakobsen and Hans Ole Christensen and Abdulaziz Al Ghonaium and Harry N White and John L. Smith and Roland J. Levinsky and Robin R Ali and Christine Kinnon and Adrian J. Thrasher},
  journal={The Lancet},

Tables from this paper

Safety Modality for X-linked Severe Combined Immunodeficiency Gene

Proof-of-principle of a safety mechanism for SCID-X1 gene therapy that would allow elimination of gene-corrected cells in a patient upon observation of monoclonal outgrowth is shown.

Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease

This review provides an overview about the different gene therapy approaches used over the last 20 years to treat SCID-X1 patients, particularly focusing on lymphoid immune reconstitution, as well as the developments that have improved the process and outcomes.

Efficacy of gene therapy for X-linked severe combined immunodeficiency.

After nearly 10 years of follow-up, gene therapy was shown to have corrected the immunodeficiency associated with SCID-X1 and may be an option for patients who do not have an HLA-identical donor for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable.

Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy.

This is the first demonstration that in vivo gene therapy targeting HSCs can restore both cellular and humoral immunity in a large-animal model of a fatal immunodeficiency, and achievement of durable immune reconstitution in XSCID dogs is demonstrated.

A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.

This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1 and the long-term effect of this therapy on leukemogenesis remains unknown.

Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.

The reduced mutagenic potential conferred by SIN vector configurations and alternative non-LTR-based regulatory elements, together with proven efficacy in correction of cellular defects provides an important platform for development of the next phase of clinical trials for SCID-X1.

[Gene therapy of SCID-X1].

Activation of cellular proto-oncogenes by accidental integration of the gene vector has been identified as the underlying mechanism and improved vector technology in combination with other protocol modifications may reduce the risk of this side effect.

Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?

The clinical experience of gene therapy for SCID-X1 is put into perspective, with the development and implementation of new generations of safer vectors such as self-inactivating gammaretroviral or lentiviral vectors as well as major advances in integrome knowledge.

Gene therapy for severe combined immunodeficiencies

A number of clinical trials have established that ex vivo gene transfer into haematopoietic progenitor cells allows effective recovery of immune defects and that gene therapy can offer a successful alternative to transplantation.

Gene Therapy Studies in a Canine Model of X-Linked Severe Combined Immunodeficiency

These studies demonstrate that durable T cell reconstitution and thymopoiesis with no evidence of any serious adverse events and, in contrast to the human XSCID patients, sustained marking in myeloid cells and B cells with Reconstitution of normal humoral immune function can be achieved for up to 5 years without any pretreatment conditioning.



Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.

Ex vivo gene therapy with gamma(c) can safely correct the immune deficiency of patients with X-linked severe combined immunodeficiency and allow patients to have a normal life.

Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Transplantation of marrow from a related donor is a life-saving and life-sustaining treatment for patients with any type of severe combined immunodeficiency, even when there is no HLA-identical donor.

Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

The vestigial thymus in infants with severe combined immunodeficiency is functional and can produce enough T cells after bone marrow transplantation to provide normal immune function.

Intrinsic defects of B cell function in X‐linked severe combined immunodeficiency

Although hematopoietic stem cell transplantation restores a diverse repertoire of class‐switched B cell clones, on further analysis these are almost all of donor origin, this suggests that host B cells, which predominate after unconditioned transplantation, are still defective even in the presence of normal T cells.

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

The sustained correction of X-linked severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc gene into CD34+ cells in four of five patients with the disease has been reported.

Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions, and lower toxic metabolites, indicating the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

Immunobiology and immunotherapeutic implication of syneneic/autologous graft‐versus‐host disease

Although the induction of syngeneic/autologous GVHD is an untoward effect of CsA immunosuppression, mobilization of these autoimmune mechanisms provides a promising immunotherapeutic approach for certain neoplastic diseases.

Understanding the alloresponse: new approaches to graft-versus-host disease prevention.

This report will focus on mechanisms as they relate to the pathophysiology of acute GVHD, which has distinctive clinical and pathologic manifestations that mimic autoimmune disease.